Is Cyclo Therapeutics Stock a Good Investment?
Cyclo Therapeutics Investment Advice | CYTHW |
- Examine Cyclo Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Cyclo Therapeutics' leadership team and their track record. Good management can help Cyclo Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Cyclo Therapeutics' business and its evolving consumer preferences.
- Compare Cyclo Therapeutics' performance and market position to its competitors. Analyze how Cyclo Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Cyclo Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Cyclo Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Cyclo Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Cyclo Therapeutics is a good investment.
Sell | Buy |
Sell
Market Performance | OK | Details | |
Volatility | Out of control | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Cyclo Therapeutics Stock
Researching Cyclo Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company had not issued any dividends in recent years.
To determine if Cyclo Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cyclo Therapeutics' research are outlined below:
| Cyclo Therapeutics is way too risky over 90 days horizon | |
| Cyclo Therapeutics has some characteristics of a very speculative penny stock | |
| Cyclo Therapeutics appears to be risky and price may revert if volatility continues | |
| Cyclo Therapeutics has accumulated 1.03 M in total debt. Cyclo Therapeutics has a current ratio of 0.85, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Note, when we think about Cyclo Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the revenue of 1.08 M. Net Loss for the year was (20.06 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Cyclo Therapeutics has accumulated about 2.24 M in cash with (16.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cyclo Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Cyclo Therapeutics Completes Phase 3 Trial Enrollment, Plans 2025 NDA Filing Amid Merger CYTH Stock News - StockTitan |
Cyclo Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 62.76 M.Market Cap |
|
Cyclo Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.51) | (1.44) | |
| Return On Capital Employed | (4.20) | (4.40) | |
| Return On Assets | (1.51) | (1.44) | |
| Return On Equity | (4.22) | (4.43) |
Determining Cyclo Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Cyclo Therapeutics is a good buy. For example, gross profit margin measures Cyclo Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cyclo Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Cyclo Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cyclo Therapeutics. Check Cyclo Therapeutics' Beneish M Score to see the likelihood of Cyclo Therapeutics' management manipulating its earnings.
Evaluate Cyclo Therapeutics' management efficiency
Cyclo Therapeutics has return on total asset (ROA) of (2.8249) % which means that it has lost $2.8249 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (226.6391) %, meaning that it generated substantial loss on money invested by shareholders. Cyclo Therapeutics' management efficiency ratios could be used to measure how well Cyclo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to -1.44 in 2024. Return On Capital Employed is likely to drop to -4.4 in 2024. At this time, Cyclo Therapeutics' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to climb to about 2.8 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 36.4 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.29 | 0.28 | |
| Tangible Book Value Per Share | 0.29 | 0.28 | |
| Enterprise Value Over EBITDA | (0.89) | (0.93) | |
| Price Book Value Ratio | 5.46 | 7.66 | |
| Enterprise Value Multiple | (0.89) | (0.93) | |
| Price Fair Value | 5.46 | 7.66 | |
| Enterprise Value | 17.8 M | 18.6 M |
Examining the leadership quality of Cyclo Therapeutics offers valuable insights into its operational efficiency and financial health. This analysis assists investors in making informed decisions regarding the stock.
Beta (0.38) |
Basic technical analysis of Cyclo Stock
As of the 26th of November, Cyclo Therapeutics shows the risk adjusted performance of 0.0893, and Mean Deviation of 10.66. Cyclo Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Cyclo Therapeutics market risk adjusted performance, variance, as well as the relationship between the Variance and potential upside to decide if Cyclo Therapeutics is priced correctly, providing market reflects its regular price of 0.14 per share. As Cyclo Therapeutics appears to be a penny stock we also recommend to validate its total risk alpha numbers.Cyclo Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cyclo Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cyclo Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cyclo Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Toig Randall M. over a week ago Acquisition by Toig Randall M. of 3350 shares of Cyclo Therapeutics at 1.28 subject to Rule 16b-3 | ||
Wong Vivien over a month ago Disposition of tradable shares by Wong Vivien of Cyclo Therapeutics subject to Rule 16b-3 | ||
Strattan Ce Rick over two months ago Acquisition by Strattan Ce Rick of 8209 shares of Cyclo Therapeutics subject to Rule 16b-3 | ||
Ostronic Francis Patrick over six months ago Acquisition by Ostronic Francis Patrick of 3350 shares of Cyclo Therapeutics at 1.28 subject to Rule 16b-3 | ||
Joshua Fine over six months ago Acquisition by Joshua Fine of 41036 shares of Cyclo Therapeutics at 1.28 subject to Rule 16b-3 | ||
Shanahan William S over six months ago Acquisition by Shanahan William S of 25971 shares of Cyclo Therapeutics subject to Rule 16b-3 |
Understand Cyclo Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Cyclo Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0893 | |||
| Market Risk Adjusted Performance | 3.51 | |||
| Mean Deviation | 10.66 | |||
| Semi Deviation | 12.08 | |||
| Downside Deviation | 28.01 | |||
| Coefficient Of Variation | 963.04 | |||
| Standard Deviation | 20.07 | |||
| Variance | 402.63 | |||
| Information Ratio | 0.0973 | |||
| Jensen Alpha | 2.0 | |||
| Total Risk Alpha | (1.09) | |||
| Sortino Ratio | 0.0697 | |||
| Treynor Ratio | 3.5 | |||
| Maximum Drawdown | 126.19 | |||
| Value At Risk | (31.54) | |||
| Potential Upside | 46.07 | |||
| Downside Variance | 784.46 | |||
| Semi Variance | 145.89 | |||
| Expected Short fall | (31.41) | |||
| Skewness | 1.24 | |||
| Kurtosis | 4.88 |
| Risk Adjusted Performance | 0.0893 | |||
| Market Risk Adjusted Performance | 3.51 | |||
| Mean Deviation | 10.66 | |||
| Semi Deviation | 12.08 | |||
| Downside Deviation | 28.01 | |||
| Coefficient Of Variation | 963.04 | |||
| Standard Deviation | 20.07 | |||
| Variance | 402.63 | |||
| Information Ratio | 0.0973 | |||
| Jensen Alpha | 2.0 | |||
| Total Risk Alpha | (1.09) | |||
| Sortino Ratio | 0.0697 | |||
| Treynor Ratio | 3.5 | |||
| Maximum Drawdown | 126.19 | |||
| Value At Risk | (31.54) | |||
| Potential Upside | 46.07 | |||
| Downside Variance | 784.46 | |||
| Semi Variance | 145.89 | |||
| Expected Short fall | (31.41) | |||
| Skewness | 1.24 | |||
| Kurtosis | 4.88 |
Consider Cyclo Therapeutics' intraday indicators
Cyclo Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cyclo Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Cyclo Therapeutics time-series forecasting models is one of many Cyclo Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cyclo Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Cyclo Stock media impact
Far too much social signal, news, headlines, and media speculation about Cyclo Therapeutics that are available to investors today. That information is available publicly through Cyclo media outlets and privately through word of mouth or via Cyclo internal channels. However, regardless of the origin, that massive amount of Cyclo data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Cyclo Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Cyclo Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Cyclo Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Cyclo Therapeutics alpha.
Cyclo Therapeutics Corporate Management
| Michael Lisjak | Global Development | Profile | |
| George Fails | Ex Mang | Profile | |
| Jeffrey Tate | Chief COO | Profile | |
| Scott Fine | CEO Director | Profile | |
| Lori McKenna | Global Advocacy | Profile |
Additional Tools for Cyclo Stock Analysis
When running Cyclo Therapeutics' price analysis, check to measure Cyclo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclo Therapeutics is operating at the current time. Most of Cyclo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cyclo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclo Therapeutics' price. Additionally, you may evaluate how the addition of Cyclo Therapeutics to your portfolios can decrease your overall portfolio volatility.